glp-1 news employers Agonists: Managing Employee Health and Employer Costs GLP-1 drug use nearly quadruples

Developed by the Danish pharmaceutical company Novo Nordisk, Saxenda was approved by the FDA in December 2014 for the treatment of chronic weight management, combined with a reduced-calorie diet and physical activity

Clinical trials showed average weight loss of 510% of body weight

Studies on GLP-1 drugs, specifically Semaglutide and Tirzepatide, reveal a clear trend: patients who stop these medications abruptly tend to regain most of the lost weight

NHS services (such as NHS Online Pharmacy and NHS Pharmacy First) are available to patients in England only

One of the main predictors of whether you are a viable candidate to need Semaglutide GLP-1 injections for weight loss is if you are considered obese, which is indicated by a body mass index of 30 or over

Side effects are typically mild and manageable